Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors. Read More
Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial
Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a significant 38.3% reduction in proteinuria, as measured ... Read More